YTYang Fei Tan

Yang Fei Tan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yang Fei Tan has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Nanotechnology in mRNA Vaccines

    by Yang Fei Tan, Subbu Venkatraman

    The phenomenal success and worldwide acceptance of mRNA vaccines against COVID-19 has highlighted one remarkable aspect of these vaccines — the ease of scale-up and the fast manufacturing of the vaccines. The timeline from starting the development (by making the plasmid DNA construct for the spike protein) to FDA Emergency Use authorization was accomplished in less than two years. The reasons for this “Warp Speed” accomplishment are varied, and we will go through each step to highlight where translation was rapid.

  • Targeting efficiency of nanoliposomes on atherosclerotic foam cells: polyethylene glycol-to-ligand ratio effects

    by Anastasia Darwitan, Yang Fei Tan, Yee Shan Wong, Anu Maashaa Nedumaran, Bertrand Czarny, Subbu Venkatraman

    Nanoparticles that actively target tissues, with ligands attached at the extremity of polyethylene glycol (PEG) spacer, are a promising strategy to enhance target cell specificity and internalizati...


  • Design and in vitro release study of siRNA loaded Layer by Layer nanoparticles with sustained gene silencing effect

    by Yang Fei Tan, Ying Shi Lee, Li-Fong Seet, Kee Woei Ng, Tina T. Wong, Subbu Venkatraman

    Objectives: Clinical translation of siRNA therapeutics has been severely limited due to the lack of stable and sustained siRNA delivery systems. Furthermore, when nanocarrier systems with siRNA are administered systemically to treat diseases, insufficient doses reach the target tissue. Here we report the successful development of a new nanocarrier system for the management of fibrosis. Methods: The new carrier has a hydroxyapatite core, with alternating layers of siRNA and a cationic peptide. The siRNA used here targets secreted protein acidic and rich in cysteine (SPARC), a key matricellular protein involved in the regulation of collagen fibrillogenesis and assembly. We have also used FRET studies to elucidate the fate of the particles inside cells, including the mechanistic details of layer-by-layer detachment. Results: In vitro studies using murine conjunctiva fibroblasts show sustained release over 2 weeks, and that such released siRNA sustained SPARC knockdown without affecting cell growth, and maintained siRNA presence in the cells for at least two weeks with a single-dose treatment. Release studies of siRNA from particles in vitro gave insight on how the particles delivered prolonged gene-silencing effects. Conclusion: A single treatment of the layer-by-layer nanoparticle designed can achieve sustained gene silencing over 2 weeks. Localized delivery of stabilized siRNA with sustained-release capabilities opens the door for many other applications of siRNA-based gene regulation.